Updated outcomes from phase II Chinese study of lorlatinib 100mg qday in previously treated #ALK NSCLC Clinical Lung Cancer. PFS post crizotinib was 26.3m. PFS after other ALK TKIs was 5.6m. No new safety signals with longer 3y f/u.

clinical-lung-cancer.com/article/S1525-…

Certainly confounders here, but interesting look at immediate vs deferred systemic therapy in pts with pleural mesothelioma Clinical Lung Cancer. In this group, 58% of deferred pts eventually had systemic therapy. OS longer in deferred group (20.6m vs 11.5m).

clinical-lung-cancer.com/article/S1525-…

Novel EGFR germline mutation in an individual with lung cancer. Germline mutations in lung cancer is a developing paradigm with the potential to change screening guidelines.

Himil Mahadevia Janakiraman Subramanian Saint Luke's Cancer Institute Ben Ponvilawan Clinical Lung Cancer

clinical-lung-cancer.com/article/S1525-…

🔥COPILOT: Completion Of Pembrolizumab In advanced NSCLC
🎙️Dr. A Fantoni Clinical Lung Cancer
🎯Real world Outcomes after Two years of therapy ()
✅Observational study
✅Primary: PFS
✅AUstralian Registry and biObank of thoRacic cAncers (AURORA)
#LCSM OncoAlert
clinical-lung-cancer.com/article/S1525-…

Real world description of pts who completed 2y of 1L pembrolizumab Clinical Lung Cancer (n=71). In this group, RR 79%, mPFS 46.1m, 60% with #KRAS mt. 24% received local ablation for oligoprogression. 28% progressed after stopping pembro (more if PDL1 < 1%).

clinical-lung-cancer.com/article/S1525-…

A review published in Clinical Lung Cancer provides a comprehensive summary of published studies assessing the incidence and mortality of QT-interval prolongation, Torsades de Pointes, and heart failure in patients with NSCLC treated with EGFR TKIs.

bit.ly/43VrQD3

Can radiomics help predict outcomes after neoadjuvant chemotherapy?

Check out a new article titled 'Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for NSCLC: A Retrospective Study'

bit.ly/49y49Ce

According to the Danish Lung Cancer Registry, the risk of venous thromboembolism (VTE) is < 6% for stage IIIA and to up to 12.5% in stage IV.

The risk of VTE varies by stage and treatment of NSCLC, with the highest risk during the first six months.

bit.ly/43TQIv0

Real-world outcomes with neoadjuvant chemotherapy or chemoradiation for resectable stage II-III NSCLC Clinical Lung Cancer from Dr. donington et al. rwEFS 17.6m, 5y rwEFS 21%, 71% with recurrence in follow up. Expect better with immunotherapy.

clinical-lung-cancer.com/article/S1525-…

Efficacy of EGFR-TKI therapy in patients with metastatic EGFR-mutant NSCLC and poor performance status: Findings from the Japanese Lung Cancer Registry Database

Full article: bit.ly/3IOqrV5

Primary pulmonary lymphoepithelial carcinoma (LEC) is a rare form of lung cancer, often associated with Epstein Barr virus (EBV)

Explore a case report discussing the use of neoadjuvant chemoimmunotherapy prior to the resection of primary pulmonary LEC

bit.ly/3Tu0kYG

An analysis of US electronic health records on the clinical characteristics, treatment patterns, and outcomes of patients with HER2-mutant advanced NSCLC diagnosed between 2016 and 2020

Link to the full article: bit.ly/3vnimnq

ETV6-NTRK2 fusion in a patient with metastatic pulmonary atypical carcinoid successfully treated with entrectinib: A case report and review of the literature

bit.ly/3TxE28s

Update on efficacy of POSEIDON (first-line durvalumab +/- tremelimumab + chemotherapy vs chemo in NSCLC) by PD-L1 strata Clinical Lung Cancer. Durva + treme + chemo improved OS for both PD-L1 ≥1% (HR 0.76) and PD-L1 negative (HR 0.77). FDA approved 11/10/22.

clinical-lung-cancer.com/article/S1525-…

published in Clinical Lung Cancer on lung cancer screening discussions! More #radonc needs to be talking about LCS! #lungcancer #cancerscreening

Perioperative ICI regimens might be better in squamous nsclc Clinical Lung Cancer Saint Luke's Cancer Institute

sciencedirect.com/science/articl…

Report Clinical Lung Cancer shows improving lung cancer survival in the Veterans Administration. 54,922 veterans with lung cancer 2010-17: increases in early detection (stage I: 18% to 30%), improved survival across stages, similar for Black & white veterans.

clinical-lung-cancer.com/article/S1525-…

Updated review on #EGFR exon 20 insertion NSCLC Clinical Lung Cancer including the first-line PAPILLON regimen and emerging targeted agents in development. #LCSM #EGFR ex20

clinical-lung-cancer.com/article/S1525-…

Look at characteristics of immunotherapy response in NSCLC Clinical Lung Cancer. Compared 37 long-term responses (OS ≥ 3y w/ IO) & 35 without response (OS 6-12m w/ IO). Responders with more irAE & #KRAS . No difference in age, sex, race, BMI, liver mets, PDL1.

clinical-lung-cancer.com/article/S1525-…

Dr. Ravi Salgia nicely summarizes unmet needs for our patients with MET exon 14 skipping mNSCLC

He highlighted a very HIGH-YIELD illustration from a review article in Clinical Lung Cancer that I recommend bookmarking! #TTLC24 #LCSM OncoAlert Oncology Brothers